A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria:

- Histologically confirmed B-cell Chronic Lymphocytic Leukemia (CLL) according to the
National Cancer Institute criteria; Eastern Cooperative Oncology Group (ECOG)
performance status of 0, 1, or 2; Adequate hematological function

Exclusion Criteria:

- Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational, or hormonal
therapy for treatment of lymphoma within 28 days prior to treatment;

- Exposure to bendamustine within the 180 days before study enrollment

- Prior autologous or allogeneic stem cell transplantation (SCT);

- Clinically significant abnormality on electrocardiogram (ECG) as determined by the
treating physician or medical monitor;

- History of other invasive malignancy within 5 years except for localized/in situ
carcinomas;

- Evidence of active infection, Confirmed current central nervous system involvement by
leukemia or lymphoma;